This month, mental health professionals from across the country gathered in New York, New York, for a pair of conferences that addressed advances in treating mental health disorders. Below are 5 key takeaways from the meetings on new directions in the field.
This month, mental health professionals from across the country gathered in New York, New York, for a pair of conferences that addressed advances in treating mental health disorders. Below are 5 key takeaways from the meetings on new directions in mental health care.
1. Depression might be fundamentally different in men and women
At the opening plenary of the 73rd Annual Scientific Convention of the Society of Biological Psychiatry (SOBP) meeting in New York City, Eric J. Nestler, MD, PhD, explained that depression may be fundamentally different in male and female patients.
Nestler, the Nash Family Professor of Neuroscience and director of the Friedman Brain Institute, explained that, in examining tissue from 2 brain banks, researchers have found more genetic abnormalities in the brains of males with depression than in the brains of females with the same diagnosis, and there was only a 5% to 10% concordance in gene overlap in these samples. This research, he suggested, may make a compelling case for sex-specific targeted therapies for depression.
2. A new treatment for depression shows reduced abuse potential
Not all patients have an adequate response to existing pharmacological treatments for major depressive disorder, and concerns linger about the abuse potential of some agents. At the SOBP meeting, researchers presented findings that adding an opioid receptor antagonist lowers the abuse potential of an adjunctive drug therapy for major depressive disorder.
ALKS 5461, an investigational drug therapy, combines buprenorphine with samidorphan, a µ-opioid receptor antagonist. In a study of nondependent, opioid-experienced volunteers, the incidence of euphoria-related adverse events was as low for the study drug as it was for placebo, and there was no evidence of dependence or withdrawal from the drug.
Separate research, presented at the American Psychiatric Association's (APA's) 2018 Annual Meeting, demonstrated that the drug has a durable antidepressant effect up to 52 weeks.
3. Mental health care must target primary prevention
Benjamin G. Druss, MD, of the Rollins School of Public Health at Emory University, explained during a session of the APA meeting, explained that mental healthcare, which currently focuses on preventing disability or bad outcomes once a patient already has a mental health disorder, needs to shift its focus to primary prevention work that applies to whole populations. Targets for action include social factors and how social determinants of health lead to other problems. It requires going “way upstream,” he explained, to address issues related to the environment, poverty, and adverse childhood events.
4. Telepsychiatry fills in gaps in psychiatric care in underserved areas
Also at the APA meeting, representatives of Project Extension for Community Healthcare Outcomes (ECHO), a program that delivers psychiatric care to underserved patients in the United States and Canada, explained that telepsychiatry can expand access to much needed care, particularly in rural areas.
The ECHO program uses a model in which a 2-hour clinic is held every week, and primary care physicians dial in to consult with psychiatric specialists. The clinic includes a discussion on best practices and a more detailed look at anonymized cases. Finally, the specialists provide recommendations for implementation that primary care physicians can use in practice.
5. Digital innovations demonstrate positive outcomes in treating common mental health issues
Finally, at the APA meeting, Kathryn M. Salisbury PhD, executive vice president of the Mental Health Association of New York City, explained that her organization’s platform, iHELP Sandy, which was developed and rolled out in the wake of superstorm Sandy, enrolled over 4000 individuals in digital services to treat depression, anxiety, and other mental health needs in the wake of the disaster. Through April 2016, said Salisbury, 59% of the individuals engaged in the iHELP Sandy program showed an improvement from baseline of at least 24%, and 89% of individuals who had severe impairment had improved by 44%.
Eculizumab Biosimilar ABP 959 Demonstrates Similarity to Reference in Patients With PNH
December 6th 2023ABP 959, an eculizumab biosimilar in development, has demonstrated similar efficacy and pharmacokinetics to the reference product for patients with paroxysmal nocturnal hemoglobinuria (PNH), according to research at the 2023 American Society of Hematology Annual Meeting.
Read More
Humana Report Shows Benefits of Value-Based Care for Patients, Physicians
December 6th 2023Patients seen at value-based care clinics received more preventive screenings and had lower risks of hospitalization and emergency room visits, according to Humana’s 10th annual value-based care report.
Read More
Race/Ethnicity May Influence Local Recurrence in DCIS, Adjuvant Treatment
December 6th 2023Disparities in 10-year local recurrence following breast-conserving surgery were seen among women with ductal carcinoma in situ (DCIS) treated over a nearly 4-decade span at Memorial Sloan Kettering Cancer Center, with Black women having the highest rate.
Read More